ANNOVIS BIO, INC. | Item 8.01 | Other Information. |
As disclosed on the Form 8-K filed with the Securities and Exchange Commission (the "Commission") on March 15, 2024, Annovis Bio, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with an institutional investor (the "Buyer") on March 15, 2024, pursuant to which the Company agreed to issue and sell to Investors an aggregate of 114,911 shares of Common Stock, 0.0001 par value per share (the "Common Shares") at $8.92 per share (the "Offering").
On March 19, 2024, the Company closed the Offering and raised $1,025,000 in gross proceeds from the Offering. The Common Shares were issued pursuant to a currently effective shelf registration statement on Form S-3 (Registration No. 333-276814), which was filed with the United States Securities and Exchange Commission on February 1, 2024, as amended on February 12, 2024 and was declared effective on February 12, 2024.
Attachments
- Original Link
- Permalink
Disclaimer
Annovis Bio Inc. published this content on 20 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 March 2024 10:03:21 UTC.
